docetaxel anhydrous has been researched along with maytansine in 15 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (maytansine) | Trials (maytansine) | Recent Studies (post-2010) (maytansine) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 815 | 96 | 592 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 14 (93.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Niculescu-Duvaz, I | 1 |
| Dixon, JM; Symmans, WF; Verrill, M; Wilson, V | 1 |
| Bianchi, GV; Chu, YW; Dirix, L; Guardino, E; Hurvitz, SA; Kocsis, J; Lu, J; Ng, V; Perez, EA; Song, C; Tong, B; Vinholes, J | 1 |
| Dirix, LY; Dirix, M; Huget, P; Rutten, A | 1 |
| Belbaraka, R; Elomrani, A; Ismaili, N; Khouchani, M; Tahri, A | 1 |
| Chandarlapaty, S; Crews, JR; Davidson, NE; Esteva, FJ; Giordano, SH; Gonzalez-Angulo, AM; Kirshner, JJ; Krop, I; Levinson, J; Lin, NU; Modi, S; Patt, DA; Perez, EA; Perlmutter, J; Ramakrishna, N; Temin, S; Winer, EP | 1 |
| Amler, LC; Gianni, L; Guardino, E; Hurvitz, SA; Mundt, KE; Ng, V; Perez, EA | 1 |
| Albanell, J; Campone, M; Chang, JC; de Haas, SL; Dewar, JA; Fumoleau, P; Garcia-Saenz, JA; Limentani, SA; Martin, M; Patre, M; Strasak, A; Xu, J | 1 |
| Chuang, JC; Das, M; Diehn, M; Huang, J; Liang, Y; Neal, JW; Stehr, H; Wakelee, HA | 1 |
| Boon, E; Flucke, UE; van Boxtel, W; van den Hoogen, FJA; van Herpen, CML; Weijs, WLJ | 1 |
| Ali, AA; Chavarri-Guerra, Y; de Lima Lopes, G; Diaby, V; Ezendu, K; Soto-Perez-de-Celis, E; Williams, KJ | 1 |
| Afenjar, K; Beckmann, MW; Boileau, JF; Campone, M; Fresco, R; Harbeck, N; Helms, HJ; Huang, CS; Hurvitz, SA; Jung, KH; Lin, YG; Martin, M; Slamon, D; Sparano, J; Stroyakovskiy, D; Symmans, WF; Thompson, AM; Valero, V; Wildiers, H; Xu, J | 1 |
| Adamo, V; Franchina, T; Mastroeni, G; Ricciardi, GRR; Russo, A; Santacaterina, A; Schifano, S | 1 |
| Bernöster, K; Häder, T; Herbener, P; Schönfeld, K; Schüttrumpf, J; Uherek, C; Zuber, C | 1 |
| Chan, KKW; Earle, CC; Eisen, A; Gong, IY; Trudeau, ME; Yan, AT | 1 |
4 review(s) available for docetaxel anhydrous and maytansine
| Article | Year |
|---|---|
Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Carboplatin; Clinical Trials as Topic; Docetaxel; Female; Fluorouracil; Genes, erbB-2; Humans; Immunoconjugates; Maytansine; Mice; Mice, SCID; Receptor, ErbB-2; Taxoids; Trastuzumab | 2010 |
Trastuzumab emtansine in breast cancer.
Topics: Ado-Trastuzumab Emtansine; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Immunoconjugates; Lapatinib; Maytansine; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2013 |
[Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer].
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gene Amplification; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Neovascularization, Pathologic; Prognosis; Quinazolines; Receptor, ErbB-2; Taxoids; TOR Serine-Threonine Kinases; Trastuzumab | 2013 |
Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
Topics: Ado-Trastuzumab Emtansine; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Comorbidity; Docetaxel; Drug Administration Schedule; Evidence-Based Medicine; Female; Health Status Disparities; Healthcare Disparities; Humans; Lapatinib; Letrozole; Maytansine; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Societies, Medical; Taxoids; Trastuzumab; Treatment Outcome; Triazoles; United States | 2014 |
4 trial(s) available for docetaxel anhydrous and maytansine
| Article | Year |
|---|---|
Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Maytansine; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2013 |
Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Maytansine; Middle Aged; Receptor, ErbB-2; Retrospective Studies; RNA, Messenger; Taxoids; Trastuzumab; Treatment Outcome | 2014 |
Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Maytansine; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Receptor, ErbB-2; Taxoids; Trastuzumab | 2016 |
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Topics: Ado-Trastuzumab Emtansine; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia; Biomarkers, Tumor; Breast Neoplasms; Canada; Carboplatin; Chemotherapy, Adjuvant; Docetaxel; Europe; Female; Humans; Maytansine; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Receptor, ErbB-2; Taxoids; Time Factors; Trastuzumab; Treatment Outcome; United States | 2018 |
7 other study(ies) available for docetaxel anhydrous and maytansine
| Article | Year |
|---|---|
HER2 testing in patients with breast cancer.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Immunohistochemistry; Lapatinib; Maytansine; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2012 |
ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.
Topics: Adenocarcinoma; Ado-Trastuzumab Emtansine; Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Dosage; Genes, erbB-2; Humans; Lung Neoplasms; Male; Maytansine; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Quinazolines; Retrospective Studies; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2017 |
Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metastatic salivary duct carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Maytansine; Receptor, ErbB-2; Salivary Ducts; Taxoids; Trastuzumab | 2017 |
Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Female; Humans; Maytansine; Mexico; Receptor, ErbB-2; Taxoids; Trastuzumab | 2017 |
Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Female; Humans; Maytansine; Meningeal Neoplasms; Middle Aged; Receptor, ErbB-2; Taxoids; Trastuzumab | 2018 |
Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast; Cell Line, Tumor; Docetaxel; Female; Humans; Immunoconjugates; Maytansine; Mice; Mice, Nude; Paclitaxel; Syndecan-1; Treatment Outcome; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2018 |
Comparison of outcomes in a population-based cohort of metastatic breast cancer patients receiving anti-HER2 therapy with clinical trial outcomes.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Follow-Up Studies; Humans; Maytansine; Middle Aged; Neoplasm Metastasis; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Trastuzumab | 2020 |